betahistine has been researched along with Recrudescence in 5 studies
Betahistine: A histamine analog and H1 receptor agonist that serves as a vasodilator. It is used in MENIERE DISEASE and in vascular headaches but may exacerbate bronchial asthma and peptic ulcers.
betahistine : An aminoalkylpyridine that is pyridine substituted by a 2-(methylamino)ethyl group at position 2. It acts as a histamine agonist and a vasodilator, and is thought to improve the microcirculation of the labyrinth, resulting in reduced endolymphatic pressure. It is used (generally as the hydrochloride or mesylate salt) to reduce the symptoms of vertigo, tinnitus, and hearing loss associated with Meniere's disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this double-blind, randomized, multicenter study was to compare the efficacy of betahistine dihydrochloride (BH) and flunarizine (FL) using the Dizziness Handicap Inventory (DHI), a validated self-assessment questionnaire that has not previously been used in a clinical trial to evaluate antivertigo drugs." | 9.10 | Double-blind, randomized, multicenter study comparing the effect of betahistine and flunarizine on the dizziness handicap in patients with recurrent vestibular vertigo. ( Albera, R; Ciuffolotti, R; De Benedittis, G; Di Cicco, M; Grazioli, I; Melzi, G; Mira, E; Pallestrini, E; Passali, D; Serra, A; Vicini, C, 2003) |
| "A double-blind crossover study was carried out in general practice in 88 patients with peripheral vertigo of unknown origin to compare the efficacy and tolerance of 12 mg betahistine dihydrochloride and 15 mg cinnarizine." | 9.06 | A double-blind crossover study comparing betahistine and cinnarizine in the treatment of recurrent vertigo in patients in general practice. ( Deering, RB; Downey, LJ; Prescott, P; Simmons, RL, 1986) |
| "OSVaLD (Observational Study in patients suffering from recurrent peripheral vestibular Vertigo to Assess the effect of betahistine 48 mg/day on quality of Life and Dizziness symptoms) is a 3-month, open-label, multi-national post-marketing surveillance study of betahistine 48 mg/day in the management of patients with vertigo of less than 5 years in duration." | 7.74 | Patient baseline characteristics in an open-label multinational study of betahistine in recurrent peripheral vestibular vertigo: the OSVaLD study. ( Benecke, H; Kuessner, D; Pérez-Garrigues, H, 2007) |
| "The aim of this double-blind, randomized, multicenter study was to compare the efficacy of betahistine dihydrochloride (BH) and flunarizine (FL) using the Dizziness Handicap Inventory (DHI), a validated self-assessment questionnaire that has not previously been used in a clinical trial to evaluate antivertigo drugs." | 5.10 | Double-blind, randomized, multicenter study comparing the effect of betahistine and flunarizine on the dizziness handicap in patients with recurrent vestibular vertigo. ( Albera, R; Ciuffolotti, R; De Benedittis, G; Di Cicco, M; Grazioli, I; Melzi, G; Mira, E; Pallestrini, E; Passali, D; Serra, A; Vicini, C, 2003) |
| "A double-blind crossover study was carried out in general practice in 88 patients with peripheral vertigo of unknown origin to compare the efficacy and tolerance of 12 mg betahistine dihydrochloride and 15 mg cinnarizine." | 5.06 | A double-blind crossover study comparing betahistine and cinnarizine in the treatment of recurrent vertigo in patients in general practice. ( Deering, RB; Downey, LJ; Prescott, P; Simmons, RL, 1986) |
| "OSVaLD (Observational Study in patients suffering from recurrent peripheral vestibular Vertigo to Assess the effect of betahistine 48 mg/day on quality of Life and Dizziness symptoms) is a 3-month, open-label, multi-national post-marketing surveillance study of betahistine 48 mg/day in the management of patients with vertigo of less than 5 years in duration." | 3.74 | Patient baseline characteristics in an open-label multinational study of betahistine in recurrent peripheral vestibular vertigo: the OSVaLD study. ( Benecke, H; Kuessner, D; Pérez-Garrigues, H, 2007) |
| " There was no significant difference between dosage groups regarding improvement in vertigo at any time point during the study." | 2.74 | Comparable efficacy and tolerability between twice daily and three times daily betahistine for Ménière's disease. ( Caovilla, HH; Ganança, FF; Ganança, MM, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ganança, MM | 1 |
| Caovilla, HH | 1 |
| Ganança, FF | 1 |
| Albera, R | 1 |
| Ciuffolotti, R | 1 |
| Di Cicco, M | 1 |
| De Benedittis, G | 1 |
| Grazioli, I | 1 |
| Melzi, G | 1 |
| Mira, E | 1 |
| Pallestrini, E | 1 |
| Passali, D | 1 |
| Serra, A | 1 |
| Vicini, C | 1 |
| Pérez-Garrigues, H | 1 |
| Kuessner, D | 1 |
| Benecke, H | 1 |
| Darrouzet, V | 1 |
| Bouccara, D | 1 |
| Bozorg Grayeli, A | 1 |
| Couloigner, V | 1 |
| Negrevergne, M | 1 |
| Sterkers, O | 1 |
| Deering, RB | 1 |
| Prescott, P | 1 |
| Simmons, RL | 1 |
| Downey, LJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effectiveness of Additional Protocol Exercises for Cervical Mobility and Proprioception in Vestibular Rehabilitation: a Randomized Controlled Trial[NCT02622516] | 28 participants (Actual) | Interventional | 2015-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for betahistine and Recrudescence
| Article | Year |
|---|---|
[Menière's disease. Current status].
Topics: Aged; Anti-Bacterial Agents; Betahistine; Ear, Inner; Endolymphatic Sac; Endoscopy; Gentamicins; His | 2001 |
3 trials available for betahistine and Recrudescence
| Article | Year |
|---|---|
Comparable efficacy and tolerability between twice daily and three times daily betahistine for Ménière's disease.
Topics: Administration, Oral; Adult; Aged; Betahistine; Drug Administration Schedule; Female; Histamine Agon | 2009 |
Double-blind, randomized, multicenter study comparing the effect of betahistine and flunarizine on the dizziness handicap in patients with recurrent vestibular vertigo.
Topics: Adult; Aged; Betahistine; Double-Blind Method; Drug Administration Schedule; Female; Flunarizine; Hi | 2003 |
A double-blind crossover study comparing betahistine and cinnarizine in the treatment of recurrent vertigo in patients in general practice.
Topics: Aged; Betahistine; Cinnarizine; Double-Blind Method; Drug Evaluation; Female; Humans; Male; Middle A | 1986 |
1 other study available for betahistine and Recrudescence
| Article | Year |
|---|---|
Patient baseline characteristics in an open-label multinational study of betahistine in recurrent peripheral vestibular vertigo: the OSVaLD study.
Topics: Adult; Betahistine; Female; Humans; Male; Middle Aged; Recurrence; Treatment Outcome; Vasodilator Ag | 2007 |